Theravance Biopharma, Inc. (TBPH)

18.73 +0.16 (+0.86%) USD  |  NASDAQ  |  Dec 24, 12:33
More

Theravance Biopharma SG&A Expense (TTM): 75.94M for Sept. 30, 2025

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for TBPH.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
Corcept Therapeutics, Inc. 401.86M
Perspective Therapeutics, Inc. 31.53M
Skye Bioscience, Inc. 16.93M
FibroGen, Inc. 28.80M
Myomo, Inc. 32.71M